Zevra Therapeutics, Inc. (ZVRA) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Wait for pullback to $13.38. BUY gates pass at $13.96, but near 52-week high (4.1% away) argues for a more patient entry. Engine's entry $13.38 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of... Read more
Wait for pullback to $13.38. BUY gates pass at $13.96, but near 52-week high (4.1% away) argues for a more patient entry. Engine's entry $13.38 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Deep value: 54% margin of safety. Extreme undervaluation. (held at prior verdict — engine reading is near the momentum/RSI threshold; will commit on clearer signal). Score 7.2/10, moderate confidence.
Passes 9/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear, sector concentration cap sector=healthcare 2/10). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Zevra Therapeutics, Inc.
Latest news
- NEWS Zevra Therapeutics (ZVRA) Following Russell Index Additions Is The Stock Still Undervalued - simplywall.st — simplywall.st positive
- NEWS Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' R — Stocktwits positive
- NEWS Price to sales forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView — TradingView neutral
- NEWS Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index - marketscreener.com — marketscreener.com positive
Generated 2026-07-05T07:10:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $13.38. BUY gates pass at $13.96, but near 52-week high (4.1% away) argues for a more patient entry. Engine's entry $13.38 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Deep value: 54% margin of safety. Extreme undervaluation. (held at prior verdict — engine reading is near the momentum/RSI threshold; will commit on clearer signal). Target $24.26 (+73.8%), stop $12.18 (−14.6%), A.R:R 4.9:1. Score 7.2/10, moderate confidence.
Take-profit target: $24.26 (+73.5% upside). Target $24.26 (+73.8%), stop $12.18 (−14.6%), A.R:R 4.9:1. Stop-loss: $12.18.
Near 52-week high (4.1% away).
Zevra Therapeutics, Inc. trades at a P/E of 7.0 (forward 11.7). TrendMatrix value score: 7.4/10. Verdict: Buy (Wait for Entry).
15 analysts cover ZVRA with a consensus score of 4.3/5. Average price target: $28.
What does Zevra Therapeutics, Inc. do?Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare...
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.